PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study documents failure rate of antibiotic treatment for gonorrhea

2013-01-09
(Press-News.org) CHICAGO – In an examination of the effectiveness of cefixime, the only oral cephalosporin antimicrobial recommended for treatment of Neisseria gonorrhoeae (gonorrhea) infections, researchers found a clinical treatment failure rate of nearly 7 percent for patients treated at a clinic in Toronto, according to a preliminary study published in the January 9 issue of JAMA.

"Because of Neisseria gonorrhoeae resistance to all prior first-line antimicrobial agents, cephalosporin [antibiotic] therapy with adjuvant azithromycin or doxycycline is recommended for treatment of gonorrhea," according to background information in the article. Cefixime is the only oral cephalosporin recommended for gonorrhea treatment. "An increase in the minimum inhibitory concentration [MIC; lowest concentration of an anti-microbial agent that will prevent the growth of an organism] of N. gonorrhoeae to cefixime, and to a lesser extent, an intramuscularly administered cephalosporin, ceftriaxone, has been identified in cultured isolates worldwide. The World Health Organization has sounded alarms for the threat of untreatable gonorrhea."

Vanessa G. Allen, M.D., M.P.H., of Public Health Ontario, Toronto, Canada, and colleagues conducted a study to determine whether N. gonorrhoeae strains with reduced susceptibilities to cefixime are associated with clinical failures. The study group consisted of N. gonorrhoeae culture-positive individuals identified between May 2010 and April 2011 and treated at a sexual health clinic in Toronto with cefixime as recommended by Public Health Agency of Canada guidelines. The primary outcome measure for the study was cefixime treatment failure, defined as the repeat isolation of N. gonorrhoeae at the test-of-cure visit identical to the pretreatment isolate by molecular typing and explicit denial of re-exposure.

There were 291 N. gonorrhoeae culture-positive individuals identified. Of 133 who returned for test of cure, 13 were culture positive; 9 patients were determined to have experienced cefixime treatment failure, with an overall rate of clinical treatment failure of 6.77 percent. The rate of clinical failure associated with a cefixime MIC of 0.12 μg/mL or greater was 25 percent compared with 1.90 percent of infections with cefixime MICs less than 0.12 μg/mL.

"This study presents the first series of clinical failures of gonorrhea associated with the use of cefixime in North America, identified by the concurrent strategies of routine test-of-cure and culture-based testing for N. gonorrhoeae," the authors write.

"In light of the increases in cefixime MICs among isolates of N. gonorrhoeae across North America, this study offers preliminary clinical data to support the recent CDC recommendations that cefixime is no longer optimal first-line therapy for the successful treatment of gonorrhea. As elevated MICs to ceftriaxone are also emerging, albeit at 1 to 2 MIC dilutions less than the cefixime MIC, proactive strategies for the identification of clinical failures of N. gonorrhoeae to this last commercially available agent are required."

(JAMA. 2013;309(2):163-170; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Editorial: Cephalosporin-Resistant Gonorrhea in North America

In an accompanying editorial, Robert D. Kirkcaldy, M.D., M.P.H., of the Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, and colleagues write that the findings of this study, of documented cephalosporin treatment failures in North America, although expected, "its arrival is deeply troubling; clinicians now face the emergence of cephalosporin-resistant N. gonorrhoeae without any well-studied, effective backup treatment options."

"New antibiotics for treating gonococcal infections are needed. A clinical trial sponsored by the National Institute of Allergy and Infectious Diseases examining novel combinations of existing drugs just completed enrollment, and a small study of a new oral agent is ongoing. But the antibiotic pipeline is running dry: continued investment in antibiotic development is critical. Meanwhile, the gonococcus has continued to develop the capability to defeat each new antibiotic used. The threat of drug-resistant gonorrhea is increasing and has reached North America. Clinicians, drug developers, and public health professionals must act now."

(JAMA. 2013;309(2):185-187; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

###

To contact Vanessa G. Allen, M.D., M.P.H., call Nicole Helsberg at 647-260-7466 or email nicole.helsberg@oahpp.ca. To contact editorial author Robert D. Kirkcaldy, M.D., M.P.H., call the NCHHSTP Media Office at 404-639-8895 or email NCHHSTPMediaTeam@cdc.gov.

END



ELSE PRESS RELEASES FROM THIS DATE:

Post-operative intravenous acetaminophen may help reduce use of morphine in infants

2013-01-09
CHICAGO – Among infants undergoing major surgery, postoperative use of intermittent intravenous paracetamol (acetaminophen) for the management of pain resulted in a lower cumulative morphine dose over 48 hours, according to a study appearing in the January 9 issue of JAMA. Opioid therapy for the treatment of pain is associated with adverse effects. Researchers are seeking alternative analgesic regimens in neonates and infants, according to background information in the article. Paracetamol has been proposed as an alternative, with one study showing promise. Ilse Ceelie, ...

Lung cancer patients live longer if they use beta-blockers while receiving radiotherapy

2013-01-09
Patients with non-small-cell lung cancer survive longer if they are taking beta-blockers while receiving radiotherapy, according to a study of 722 patients published in the cancer journal Annals of Oncology [1] today (Wednesday). Researchers at the University of Texas MD Anderson Cancer Center (Houston, USA) reviewed the progress and outcomes of patients who had received radiotherapy as their main or first line of treatment for cancer (known as "definitive radiotherapy" i.e. radiotherapy that is delivered at doses of 60 Gy or more, with the intention of curing the disease). ...

Cheating slime mold gets the upper hand

Cheating slime mold gets the upper hand
2013-01-09
A 'cheater' mutation (chtB) in Dictyostelium discoideum, a free living slime mould able to co-operate as social organism when food is scarce, allows the cheater strain to exploit its social partner, finds a new study published in BioMed Central's open access journal BMC Evolutionary Biology. The mutation ensures that when mixed with 'normal' Dictyostelium more than the fair share of cheaters become spores, dispersing to a new environment, and avoiding dying as stalk cells. Dictyostelium have an unusual life style. They generally live as individual amoeboid cells, eating ...

Triple mix of blood pressure drugs and painkillers linked to kidney problems

2013-01-09
Patients who take a triple combination of blood pressure drugs and common painkillers are at an increased risk of serious kidney problems, especially at the start of treatment, finds a study published on bmj.com today. Although the absolute risk for individuals is low, it is still something doctors and patients should be aware of, say the researchers. Acute kidney injury (also known as kidney failure) is a major public health concern. It occurs in more than 20% of hospital inpatients and is associated with around half of all potentially preventable deaths in hospital. ...

Cancer screening unlikely to benefit patients with a short life expectancy

2013-01-09
Breast and colorectal cancer screening should be targeted towards patients with a life expectancy greater than 10 years: for any shorter life expectancy the harms are likely to outweigh the benefits, concludes a study published on bmj.com today. The authors stress that their results "should not be used to deny screening for patients with limited life expectancy" but "should inform decision making which aims to account for patient preferences and values while maximising benefits and minimising risks." Guidelines recommend screening healthy older patients because complications ...

BMJ raises concerns over the effectiveness of a costly and invasive procedure for melanoma

2013-01-09
A special report published by the BMJ today finds that thousands of melanoma patients around the world are undergoing an expensive and invasive procedure called sentinel node biopsy, despite a lack of clear evidence and concerns that it may do more harm than good. Although not recommended for routine use in England, it has become the standard care for melanoma patients in several countries including the United States, where it was estimated to cost over $686m in 2012. Melanoma is the fifth most common cancer in the UK, affecting one in 60 people. In the US it affects ...

Reduction in air pollution from wood stoves associated with significantly reduced risk of death

2013-01-09
Male deaths from all-causes, but particularly cardiovascular and respiratory disease, could be significantly reduced with a decrease in biomass smoke (smoke produced by domestic cooking and heating and woodland fires), a paper published today on bmj.com suggests. The researchers say this could have significant impact on further interventions to reduce pollution from this source. Although a large amount of research has been carried out on the adverse health effects of air pollution, no studies have reported reductions in deaths associated with interventions to reduce ...

First oral drug for spinal cord injury improves movement in mice, study shows

2013-01-09
COLUMBUS, Ohio – An experimental oral drug given to mice after a spinal cord injury was effective at improving limb movement after the injury, a new study shows. The compound efficiently crossed the blood-brain barrier, did not increase pain and showed no toxic effects to the animals. "This is a first to have a drug that can be taken orally to produce functional improvement with no toxicity in a rodent model," said Sung Ok Yoon, associate professor of molecular & cellular biochemistry at Ohio State University and lead author of the study. "So far, in the spinal cord ...

Synthetic 'poop' can cure C. difficile infection, study finds

2013-01-09
A synthetic "poop" developed at the University of Guelph can cure nasty gastrointestinal infections caused by Clostridium difficile, a toxin-producing bacterium. A study on the artificial stool was published today in the inaugural issue of Microbiome, a new peer-reviewed science journal. The stool – a "super-probiotic" called RePOOPulate – was created by Guelph microbiologist Emma Allen-Vercoe to replace human fecal matter used in stool transplants, a known treatment for C. difficile. She made the super-probiotic from purified intestinal bacterial cultures grown ...

Earth-size planets common in galaxy

Earth-size planets common in galaxy
2013-01-09
An analysis of the first three years of data from NASA's Kepler mission, which already has discovered thousands of potential exoplanets, contains good news for those searching for habitable worlds outside our solar system. It shows that 17 percent of all sun-like stars have planets one to two times the diameter of Earth orbiting close to their host stars, according to a team of astronomers from the University of California, Berkeley, and the University of Hawaii at Manoa. This estimate includes only planets that circle their stars within a distance of about one-quarter ...

LAST 30 PRESS RELEASES:

Novel treatment combination improves progression-free survival in metastatic, estrogen-receptor-positive HER-2-negative breast cancer

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients

New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease

Sylvester Cancer Tip Sheet for October 2025

Three science and technology leaders elected to Hertz Foundation Board of Directors

Jump Trading CSO Kevin Bowers elected to Hertz Foundation Board of Directors

Former Inscripta CEO Sri Kosaraju elected to Hertz Foundation Board of Directors

Citadel’s Jordan Chetty elected to Hertz Foundation Board of Directors

McGill research flags Montreal snow dump, inactive landfills as major methane polluters

A lightweight and rapid bidirectional search algorithm

Eighty-five years of big tree history available in one place for the first time

MIT invents human brain model with six major cell types to enable personalized disease research, drug discovery

Health and economic air quality co-benefits of stringent climate policies

How immune cells deliver their deadly cargo

How the brain becomes a better listener: How focus enhances sound processing

Processed fats found in margarines unlikely to affect heart health

Scientists discover how leukemia cells evade treatment

Sandra Shi MD, MPH, named 2025 STAT Wunderkind

Treating liver disease with microscopic nanoparticles

Chemicals might be hitching a ride on nanoplastics to enter your skin

Pregnant patients with preexisting high cholesterol may have elevated CV risk

UC stroke experts discuss current and future use of AI tools in research and treatment

The Southern Ocean’s low-salinity water locked away CO2 for decades, but...

OHSU researchers develop functional eggs from human skin cells

Most users cannot identify AI bias, even in training data

Hurricane outages: Analysis details the where, and who, of increased future power cuts

Craters on surface of melanoma cells found to serve as sites for tumor killing

Research Spotlight: Mapping overlooked challenges in stroke recovery

Geographic and temporal patterns of screening for breast, cervical, and colorectal cancer in the US

[Press-News.org] Study documents failure rate of antibiotic treatment for gonorrhea